What we believe in
Hundreds of millions of people are burdened with a chronic respiratory condition – the WHO estimates that 235 million people currently have asthma, and four million die prematurely from chronic respiratory disease (COPD) every year.
Our Vision & Mission
Our Vision is to create a new generation of eco-friendly medical inhalation products to improve respiratory treatments.
Our Mission is to:
Intensify and expand the use of propellant-free and therefore eco-friendly device solutions.
Offering patients innovative SMI applications on a global scale.
Create a proprietary device platform, flexible enough to adapt to multiple indications that can be treated via the respiratory pathway.
The Soft Mist Inhalers (SMIs) created in the 1990s were revolutionary – they combined the best features of these approaches, offering an ultra-fine mist with a slow velocity and long cloud duration leading to higher amount of inhaled drug compared to other pressurised inhalers. Since then, the acceptance of SMIs has grown rapidly, and they represent a multi-billion dollar market potential.
Our Board
As a group, our Board offers profound medical, pharmaceutical/chemical, medical device and consumer product expertise. It consists of members of the Series A & B multi-national venture capital consortium, the CEO, a non-executive director, a founder’s representative and the chairman.
Our Team of Experts
Microfluidic Expert
Co-Founder
Former Credit Suisse
Partner Cukierman & Co.
Former Novartis
Former Sanofi
Former Novartis
Co-Founder
Former Hovione
Former Head of Respiratory Europe at Teva
We are currently designing and creating a propellant-free, purely mechanical device to be used for worldwide generic and non-generic pharmaceutical products.